[FLXN] Flexion Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 20.71 Change: 2.14 (11.52%)
Ext. hours: Change: 0 (0%)

chart FLXN

Refresh chart

Strongest Trends Summary For FLXN

FLXN is in the medium-term up 24% above S&P in 1 month. In the long-term down -55% below S&P in 1 year and down -69% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Flexion Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. It lead product candidate includes FX006, a sustained-release intra-articular steroid, which has completed a Phase IIb dose-ranging clinical trial to treat moderate to severe osteoarthritis (OA) pain. The company is also developing FX007, a preclinical, small-molecule TrkA receptor antagonist to address post-operative pain; and FX005, a sustained-release intra-articular p38 MAP kinase inhibitor, which has completed a Phase IIa clinical trial intended as a therapy for patients with end-stage OA pain. Flexion Therapeutics, Inc. was founded in 2007 and is headquartered in Burlington, Massachusetts.

Fundamental Ratios
Shares Outstanding EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-21.24% ROE-21.88% ROI
Current Ratio32.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.03
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-3.69 M Cash From Investing Activities-62.47 M Cash From Operating Activities-9.98 M Gross Profit
Net Profit-9.17 M Operating Profit-9.01 M Total Assets141.02 M Total Current Assets134.24 M
Total Current Liabilities4.16 M Total Debt Total Liabilities4.19 M Total Revenue
Technical Data
High 52 week28.14 Low 52 week9.68 Last close12.52 Last change-5.58%
RSI58.93 Average true range0.82 Beta1.41 Volume629.96 K
Simple moving average 20 days11.32% Simple moving average 50 days7.39% Simple moving average 200 days-18.91%
Performance Data
Performance Week-0.32% Performance Month22.15% Performance Quart-14.6% Performance Half-23.71%
Performance Year-52.81% Performance Year-to-date10.6% Volatility daily5.3% Volatility weekly11.85%
Volatility monthly24.29% Volatility yearly84.13% Relative Volume286.22% Average Volume667.88 K
New High New Low

News

2019-06-07 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-06-05 08:30:00 | Flexion Therapeutics Announces Issuance of New U.S. Patent Covering FX201 a Gene Therapy Product Candidate for the Treatment of Osteoarthritis

2019-05-30 06:58:51 | If You Had Bought Flexion Therapeutics NASDAQ:FLXN Stock A Year Ago, You'd Be Sitting On A 56% Loss, Today

2019-05-20 12:48:46 | These 3 Small-Cap Healthcare Stocks Reported Big Updates This Month

2019-05-14 16:30:00 | Flexion Therapeutics to Present at the 2019 RBC Capital Markets Global Healthcare Conference

2019-05-12 21:50:08 | Here’s What Hedge Funds Think About Flexion Therapeutics Inc FLXN

2019-05-10 13:06:21 | Flexion Therapeutics, Inc. FLXN Q1 2019 Earnings Call Transcript

2019-05-10 07:30:00 | Flexion Therapeutics Announces Publication of Pooled Analysis of Phase 2/3 Data on Use of Rescue Medication with ZILRETTA® triamcinolone acetonide extended-release injectable suspension

2019-05-09 11:58:00 | Here's Why Flexion Therapeutics Jumped as Much as 18.4% Today

2019-05-09 09:45:38 | Chevron, Conduent, Flexion, and More: Stocks in the Spotlight

2019-05-09 01:34:59 | Edited Transcript of FLXN earnings conference call or presentation 8-May-19 8:30pm GMT

2019-05-08 18:35:10 | Flexion Therapeutics FLXN Reports Q1 Loss, Lags Revenue Estimates

2019-05-08 17:25:58 | Flexion Therapeutics: 1Q Earnings Snapshot

2019-05-08 16:01:00 | Flexion Therapeutics Reports First-Quarter 2019 Financial Results and Recent Business Highlights

2019-05-08 14:30:00 | Flexion Therapeutics, Inc. to Host Earnings Call

2019-05-03 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-05-02 09:00:00 | Flexion Therapeutics Announces Upcoming Presentations at the 2019 Osteoarthritis Research Society International OARSI World Congress

2019-05-01 16:30:00 | Flexion Therapeutics to Report First-Quarter 2019 Financial Results on May 8, 2019

2019-04-25 07:58:40 | The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

2019-04-24 16:30:00 | Flexion Therapeutics Announces Publication of Analysis of Patients with Unilateral Knee OA from Pivotal Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension

2019-04-23 12:53:34 | Flexion Therapeutics, Inc. NASDAQ:FLXN: Time For A Financial Health Check

2019-04-05 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-04-03 16:30:00 | Flexion Therapeutics to Present at the 18th Annual Needham & Company Healthcare Conference

2019-04-02 07:30:00 | Flexion Therapeutics Announces Publication of Independent Data Review of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in the Journal Drugs

2019-04-01 09:00:00 | Flexion Therapeutics Announces Kerry Wentworth, Chief Regulatory Officer, Appointed to Massachusetts Biotechnology Council Board

2019-03-11 08:00:07 | Mutual Fund Managers Are Bullish On Stock Market Forecast — But Some Are Hedging Bets

2019-03-04 16:30:00 | Flexion Therapeutics to Present at the Cowen 39th Annual Health Care Conference

2019-03-04 07:00:00 | Opsens Appoints Alan Milinazzo as Executive Chairman of the Board of Directors

2019-03-01 18:47:32 | Edited Transcript of FLXN earnings conference call or presentation 28-Feb-19 9:30pm GMT

2019-03-01 16:45:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-02-28 20:20:23 | Flexion Therapeutics Inc FLXN Q4 2018 Earnings Conference Call Transcript

2019-02-28 16:01:00 | Flexion Therapeutics Reports Fourth-Quarter and Full-Year 2018 Financial Results

2019-02-26 16:30:00 | Flexion Therapeutics to Present at the 40th Annual Raymond James Institutional Investors Conference

2019-02-21 16:30:00 | Flexion Therapeutics Announces New In Vitro Data Showing Protective Effects of Triamcinolone Acetonide on Cartilage

2019-02-21 10:31:03 | Flexion Therapeutics FLXN May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2019-02-20 16:30:00 | Flexion Therapeutics to Report Fourth-Quarter and Full-Year 2018 Financial Results on February 28, 2019

2019-02-11 16:05:00 | Flexion Therapeutics Announces Publication of Data from Repeat Administration Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in Rheumatology and Therapy

2019-02-11 11:41:00 | Here's Why Flexion Therapeutics Rose 29.8% in January

2019-02-08 09:00:00 | Flexion Therapeutics to Ring Nasdaq Stock Market Opening Bell on Tuesday, February 12

2019-02-01 17:00:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-01-30 07:20:00 | Consolidated Research: 2019 Summary Expectations for Telephone and Data, EMCOR Group, Chart Industries, Alarm, Flexion Therapeutics, and Social Reality — Fundamental Analysis, Key Performance Indications

2019-01-22 16:30:00 | Flexion Therapeutics Names Christina Willwerth Chief Strategy Officer

2019-01-04 16:30:00 | Flexion Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-01-04 07:59:58 | The Daily Biotech Pulse: Novavax Reports Positive Influenza Vaccine Trial Data, Flexion Warns Of Revenue Shortfall, Retrophin's New CEO

2019-01-03 16:36:00 | Flexion shares plummet after weak revenue guidance

2019-01-03 16:01:00 | Flexion Therapeutics Announces Preliminary, Unaudited Fourth-Quarter and Full-Year 2018 Revenue and Initial Revenue Guidance for 2019

2019-01-03 12:05:21 | Raymond James: Flexion Therapeutics Estimates Are A Stretch

2019-01-03 10:26:03 | Flexion Starts Phase III Enrollment on Zilretta for Hip OA

2019-01-02 16:30:00 | Flexion Therapeutics Enrolls First Patient in Phase 3 Trial of ZILRETTA® triamcinolone acetonide extended-release injectable suspension in OA of the Hip and Reports Results from SHIP Study

2018-12-20 16:00:00 | Flexion Therapeutics to Report Preliminary Unaudited 2018 Revenue and Provide 2019 Revenue Guidance on January 3, 2019